Table 7 The selected helper T Cell epitopes of HPV L2 protein, based on binding affinity.

From: In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine

Protein Name

Position

Epitope Sequence

No. of Alleles

Top Alleles

NetMHCIIpan Average Rank Scores*

ProPred II Average Scores**

Conservancy (= > 75%)

Allergenicity

L2

102–120 Type 16

DPSIVSLVEETSFIDAGAP

9

DQA:10101

DQA:10102

8.120

1.257

Type 33: 84.2%

Type 35: 84.2%

Type 58: 84.2%

Non-allergen

100–118 Type 18

DPSIVTLIEDSSVVTSGAP

12

DRB1:0401

DRB1:0301

DRB3:0101

7.980

1.315

Type 45: 89.4%

Type 59: 89.4%

Type 39: 75.6%

Type 51: 75.6%

Non-allergen

54–69 Type 16

FFGGLGIGTGSGTGGR

8

DRB1:0402

DQA:10301

DQA:10501

7.160

1.645

Type 58: 100%

Type 18: 93.7%

Type 31: 93.7%

Type 33: 93.7%

Type 35: 93.7%

Type 59: 93.7%

Type 68: 93.7%

Type 39: 87.5%

Type 45: 87.5%

Type 51: 87.5%

Type 52: 87.5%

Type 56: 81.2%

Non-allergen

281–297

Type 16

PDFLDIVALHRPALTSR

32

DRB5:0101

DRB4:0101

DRB1:0801

DRB1:0402

4.165

2.148

Type 58: 100%

Type 31: 94.1%

Type 39: 94.1%

Type 52: 94.1%

Type 68: 94.1%

Type 33: 88.2%

Type 35: 88.2%

Type 51: 88.2%

Type 59: 88.2%

Type 16: 76.4%

Type 56: 76.4%

Non-allergen

274–290 Type 18

SDFMDIIRLHRPALTSR

26

DRB1:0101

DRB1:0103

DRB1:0801

DRB1:1501

3.493

2.864

Type 45: 94.1%

Type 35: 88.2%

Type 59: 88.2%

Type 31: 82.3%

Type 39: 82.3%

Type 51: 82.3%

Type 52: 82.3%

Type 68: 82.3%

Type 16: 76.4%

Type 33: 76.4%

Type 58: 76.4%

Non-allergen

  1. *lower rates show better binding affinity, **Higher rates show better binding affinity.